CompletedNCT03185819
Intranasal Esketamine for Imminent Suicide Risk in Adolescents
About this title
Study to Evaluate the Efficacy and Safety of 3 Fixed Doses of Intranasal Esketamine in Addition to Comprehensive Standard of Care for the Rapid Reduction of the Symptoms of Major Depressive Disorder, Including Suicidal Ideation, in Pediatric Participants Assessed to be at Imminent Risk for Suicide
Read the official source — NCT03185819This study evaluated the safety and effectiveness of Esketamine for people with depression.
Medication studyAges 9–17Multiple countries
Understand this study
What did researchers investigate?
This study evaluated the safety and effectiveness of Esketamine for people with depression.
Who was this study for?
Listed age limits: 9 years to 17 years.
- Listed locations
- Hartford and 50 more locationsSee all locations and recruitment
- Study phase
- Phase 2Usually explores whether the intervention may work, while continuing to monitor safety.
Study information
Study start dateStarted: October 5, 2017
- Recruitment status
- Completed
- Enrollment listed in the registry
- 147
- Sponsor
- Janssen Research & Development, LLC
- Sponsor type
- Other organization
- Study type
- Drug
- Intervention type
- Medication / drug
- Study phase
- Phase 2Usually explores whether the intervention may work, while continuing to monitor safety.
- Locations
- United States, France, Belgium, ...
- Age range
- From 9 Years to 17 Years
- Official registry ID
- NCT03185819
- Official title
Show the full official title
A Double-blind, Randomized, Psychoactive Placebo-controlled, Study to Evaluate the Efficacy and Safety of 3 Fixed Doses (28 mg, 56 mg and 84 mg) of Intranasal Esketamine in Addition to Comprehensive Standard of Care for the Rapid Reduction of the Symptoms of Major Depressive Disorder, Including Suicidal Ideation, in Pediatric Subjects Assessed to be at Imminent Risk for Suicide
Looking for a study you can join?
Explore recruiting studiesRecruitment & locations
CompletedHartford, United States · New Haven, United States · Atlanta, United States
44 more locations
- Chicago, United States
- Winfield, United States
- South Bend, United States
- Iowa City, United States
- Lake Charles, United States
- Baltimore, United States
- Gaithersburg, United States
- Buffalo, United States
- Chapel Hill, United States
- Winston-Salem, United States
- Cincinnati, United States
- Cleveland, United States
- Columbus, United States
- Nashville, United States
- Dallas, United States
- Brussels, Belgium
- Curitiba, Brazil
- Salvador, Brazil
- São Bernardo do Campo, Brazil
- Turvo, Brazil
- Rousse, Bulgaria
- Varna, Bulgaria
- Bron, France
- Lille, France
- Nantes, France
- Paris, France
- Budapest, Hungary
- Szeged, Hungary
- Cagliari, Italy
- Foggia, Italy
- Merano, Italy
- Messina, Italy
- Naples, Italy
- Pavia, Italy
- Trieste, Italy
- Krakow, Poland
- Warsaw, Poland
- Barcelona, Spain
- Esplugues de Llobregat, Spain
- Madrid, Spain
- Majadahonda, Spain
- Oviedo, Spain
- Pamplona, Spain
- Sabadell, Spain
Questions about this study
What did researchers investigate?
This study evaluated the safety and effectiveness of Esketamine for people with depression.
Who is behind this study?
The study sponsor is Janssen Research & Development, LLC.
Did this study involve medication?
Yes. The study involved medication, including Intranasal Placebo, Midazolam Placebo Solution, Midazolam and Esketamine.
Who was this study for?
Listed age limits: 9 years to 17 years.
